This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. ” According to IQVIA, the U.S.
Catalent snaps up Promethera’s cell therapy subsidiary, complete with a Belgian plant to help scale plasmid DNA efforts ( Endpoints ).
Two drug makers, two commercial launches — with divergent results ( STAT ).
GenericDrug Cos. Invoke FTC Restitution Limits Against AGs ( Law360 ).
It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.
It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.
5) Lynparza (Olaparib) Lynparza is a PARP inhibitor , meaning it inhibits poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. The drug is indicated for the treatment of metastatic HER2- breast cancer with inherited BRCA1 or 2 mutations, ovarian cancer and fallopian tube cancer, among others. billion, a 6.00
This post will cover the use of Truvada and its generic form for PrEP. In plain language, both emtricitabine and tenofovir disoproxil stops viral DNA production and therefore stops spreading of HIV. One important message to take away is that Truvada and equivalent genericdrugs are not 100% effective.
Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of genericdrugs and biosimilar products. animal, viral, bacterial) DNA and RNA sequences. animal, viral, bacterial) DNA and RNA sequences. Javitt & Jeffrey N.
Unlike COVID-19 tests that need to be processed through PCR machines, the new rapid test is processed through a handheld DNA analyzer. Meanwhile, Health Canada has given approval to Spartan Biosciences to start shipping its new rapid test for COVID-19 to federal and provincial governments immediately.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content